On March 8, 2022 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, reported three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, Louisiana (Press release, Gritstone Oncology, MAR 8, 2022, View Source [SID1234609677]). In the poster presentations, Gritstone representatives will review data from individualized neoantigen program, GRANITE, and the "off-the-shelf" neoantigen vaccine program, SLATE. In the oral presentation, Christine D Palmer, PhD will discuss how immunodominant human T cell responses to tumor specific neoantigens presented by the same HLA in a first-generation construct informed development of a second-generation candidate that exhibits immunogenic superiority over version 1 in preclinical models within SLATE. This optimized candidate, SLATE-KRAS, exclusively includes KRASmut epitopes and is now in Phase 2 testing in solid tumor patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstracts associated with these presentations are now available on the conference website. Details of the presentations are as follows:
Oral Presentation Details
Abstract 3578: Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back
Date/Time: Tuesday Apr 12, 2022, 2:30 PM – 4:30 PM ET
Session: Clinical Research Excluding Trials; Resistance Mechanisms & New Advances in Immunotherapeutics
Presenter: Christine D Palmer, PhD
Location: New Orleans Convention Center, Theater B
Poster Presentation Details
Abstract 4149: Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8+ T cell responses in cancer patients versus high doses
Date/Time: Wednesday Apr 13, 2022, 9:00 AM – 12:30 PM ET
Session: Clinical Research Excluding Trials; Vaccines/Immunomodulatory Agents & Interventions
Presenter: Amy Rappaport, PhD
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 34, Poster Board 13
Abstract 1238: Comprehensive ctDNA monitoring provides early signal of clinical benefit with a novel personalized neoantigen directed immunotherapy for late-stage cancer patients
Date/Time: Monday Apr 11, 2022, 9:00 AM – 12:30 PM ET
Session: Clinical Research Excluding Trials; Biomarkers Predictive of Therapeutic Benefit 1
Presenter: Matthew Davis, PhD
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 30, Poster Board 10